BridgeBio Pharma Files 8-K for Other Events

TL;DR

BridgeBio filed an 8-K, likely with financial updates. Keep an eye out.

AI Summary

BridgeBio Pharma, Inc. filed an 8-K on November 22, 2024, to report other events and financial statements. The filing does not detail specific transactions or financial results but serves as a notification of these items being submitted to the SEC.

Why It Matters

This 8-K filing indicates BridgeBio Pharma is submitting required disclosures to the SEC, which could include material updates or financial information relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not contain immediate negative or positive news.

Key Players & Entities

• BridgeBio Pharma, Inc. (company) — Registrant
• November 22, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 3160 Porter Dr., Suite 250 Palo Alto, CA 94304 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share BBIO The Nasdaq Global Se
• $18,759.12 — ce daily. The list price for ATTRuby is $18,759.12 for a 28-day supply. Forward-Looking S

Filing Documents

• ef20039071_8k.htm (8-K) — 35KB
• ef20039071_ex99-1.htm (EX-99.1) — 24KB
• 0001140361-24-047704.txt ( ) — 203KB
• bbio-20241122.xsd (EX-101.SCH) — 4KB
• bbio-20241122_lab.xml (EX-101.LAB) — 21KB
• bbio-20241122_pre.xml (EX-101.PRE) — 16KB
• ef20039071_8k_htm.xml (XML) — 4KB

01

Item 8.01. Other Events On November 22, 2024, BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") issued a press release titled "Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Attruby (acoramidis) will be available at a recommended dose of 712 mg (as two 356 mg tablets) taken twice daily. The list price for ATTRuby is $18,759.12 for a 28-day supply.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K and certain of the materials filed and furnished herewith contain forward-looking statements. Statements in this Current Report on Form 8-K or the materials furnished or filed herewith may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. The Company intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including express and implied statements regarding the significance of the FDA approval of ATTRuby, the safety, efficacy and mechanism of action of ATTRuby and other product characteristics, the availability, use, commercialization, cost and commercial and medical potential of ATTRuby, and the therapeutic potential of acoramidis for ATTR-CM, including the potential to significantly improve rates of mortality, cardiovascular-related hospitalization and quality of life, reflect the Company's current views about its plans, intentions, expectations and strategies, which are based on the information currently available to the Company and on assumptions it has made. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, it can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncert

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release titled, "ATTRuby (acoramidis), a Near Complete TTR Stabilizer ( > 90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BridgeBio Pharma, Inc. Date: November 22, 2024 By: /s/ Brian C. Stephenson Brian C. Stephenson Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR